Journal
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Volume 175, Issue -, Pages 281-293Publisher
ELSEVIER
DOI: 10.1016/j.ijbiomac.2021.02.044
Keywords
Magnetic; Nanocomposites; Cancer; Carbohydrates; Chitosan; Therapeutics
Ask authors/readers for more resources
This article discusses the development and advantages of carbohydrate-based magnetic nanocomposites in cancer treatment, including better physicochemical properties and biocompatibility for safer and more effective cancer therapy.
The treatment of cancer includes several conventional therapies like surgery, radiation, chemotherapy, etc. but mostly associated with limitations like off-targeted action, fatigue and organ toxicity. The emergence of nanotechnology-enabled drug delivery systems shows revolutionary development to overcome the limitations of such therapies. Magnetic nanocomposites are the new area of research that consists of nanoscale magnetic materials for triggering the release of active in response to an external magnetic field. For targeted drug delivery and enhancing the biocompatibiity, effective functionalization of magnetic nanocomposites is required. Therefore, several biological molecules like carbohydrate polymers, proteins, nucleic adds, antibodies, etc. are used. This review article focuses on the insights of advances in the development of carbohydrate-based magnetic nanocomposites for safe and effective cancer treatment. Carbohydrate-based magnetic nanocomposites offer significant advantages like greater stability, higher biocompatibility and lower toxicity with better physicochemical properties such as higher magnetic moments and anisotropy, larger heating properties, etc. Magnetic nanocomposites explore in almost all the areas of cancer therapeutics for drug delivery carrier, as antineoplastic and MRI contrast agents and in photothermal. photodynamic and in combinational therapies for the development of safer nanocarriers. Such progressive trend of carbohydrate-based magnetic nanocomposites will encourage the researchers for better site-specific delivery with higher safety profile in cancer therapy. (C) 2021 Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available